Anti-Inflammatory Effects of Lysozyme Against HMGB1 in Human Endothelial Cells and in Mice

Inflammation

Volumn 38, Issue 5, 2015, Pages 1911-1924

  Lee, Wonhwa ^a,b   Ku, Sae Kwang ^c   Na, Dong Hee ^a   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

HMGB1; lysozyme; sepsis; vascular inflammation

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOZYME; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; HMGB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CELL PERMEABILIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; LUNG INJURY; MALE; MEDIATOR RELEASE; MORTALITY; MOUSE; NONHUMAN; SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHICKEN; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHICKENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MURAMIDASE;

EID: 84941178012     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0171-8     Document Type: Article

References (61)

1. Russell, J.A., and K.R. Walley. 2013. Update in sepsis 2012. American Journal of Respiratory and Critical Care Medicine 187: 1303–1307.
2. Goodwin, G.H., C. Sanders, and E.W. Johns. 1973. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. European Journal of Biochemistry 38: 14–19.
3. Lotze, M.T., and K.J. Tracey. 2005. High-Mobility Group Box 1 Protein (HMGB1): Nuclear weapon in the immune arsenal. Nature Reviews. Immunology 5: 331–342.
4. Bae, J.S. 2012. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Archives of Pharmacal Research 35: 1511–1523.
5. Hori, O., J. Brett, T. Slattery, et al. 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. Journal of Biological Chemistry 270: 25752–25761.
6. Park, J.S., D. Svetkauskaite, Q. He, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.
7. Bae, J.S., and A.R. Rezaie. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952–3959.
8. Yang, H., M. Ochani, J. Li, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.
9. Kelly, J.A., A.R. Sielecki, B.D. Sykes, M.N. James, and D.C. Phillips. 1979. X-ray crystallography of the binding of the bacterial cell wall trisaccharide NAM-NAG-NAM to lysozyme. Nature 282: 875–878.
10. Clingolani, R. 2014. Bioinspired approaches for human-centric technologies. New York: Springer.
11. Nakimbugwe, D., B. Masschalck, D. Deckers, L. Callewaert, A. Aertsen, and C.W. Michiels. 2006. Cell wall substrate specificity of six different lysozymes and lysozyme inhibitory activity of bacterial extracts. FEMS Microbiology Letters 259: 41–46.
12. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Archives of Pharmacal Research 36: 1160–1165.
13. Bae, J.S., W. Lee, J.O. Nam, J.E. Kim, S.W. Kim, and I.S. Kim. 2014. Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses. American Journal of Respiratory and Critical Care Medicine 189: 779–786.
14. Ku, S.K., M.S. Han, M.Y. Lee, Y.M. Lee, and J.S. Bae. 2014. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Reports 47: 336–341.
15. Ku, S.K., and J.S. Bae. 2014. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Archives of Pharmacal Research 37: 1454–1463.
16. Ku, S.K., and J.S. Bae. 2014. Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo. BMB Reports 47: 376–381.
17. Hofbauer, R., D. Moser, H. Salfinger, M. Frass, and S. Kapiotis. 1998. Sufentanil inhibits migration of human leukocytes through human endothelial cell monolayers. Anesthesia and Analgesia 87: 1181–1185.
18. Lee, W., H. Yoo, S.K. Ku, J.A. Kim, and J.S. Bae. 2013. Anticoagulant activities of piperlonguminine in vitro and in vivo. BMB Reports 46: 484–489.
19. Wang, H., H. Liao, M. Ochani, et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine 10: 1216–1221.
20. Rittirsch, D., M.S. Huber-Lang, M.A. Flierl, and P.A. Ward. 2009. Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocols 4: 31–36.
21. Lee, W., T.H. Kim, S.K. Ku, et al. 2012. Barrier protective effects of withaferin A in HMGB1-induced inflammatory responses in both cellular and animal models. Toxicology and Applied Pharmacology 262: 91–98.
22. Che, W., N. Lerner-Marmarosh, Q. Huang, et al. 2002. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: Role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circulation Research 90: 1222–1230.
23. Bae, J.W., and J.S. Bae. 2011. Barrier protective effects of lycopene in human endothelial cells. Inflammation Research 60: 751–758.
24. Bae, J.S., L. Yang, C. Manithody, and A.R. Rezaie. 2007. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909–3916.
25. Bae, J.S., W. Lee, and A.R. Rezaie. 2012. Polyphosphate elicits proinflammatory responses that are counteracted by activated protein C in both cellular and animal models. Journal of Thrombosis and Haemostasis 10: 1145–1151.
26. Lee, W., S.K. Ku, J.A. Kim, T. Lee, and J.S. Bae. 2013. Inhibitory effects of epi-sesamin on HMGB1-induced vascular barrier disruptive responses in vitro and in vivo. Toxicology and Applied Pharmacology 267: 201–208.
27. Ozdulger, A., I. Cinel, O. Koksel, et al. 2003. The protective effect of N-acetylcysteine on apoptotic lung injury in cecal ligation and puncture-induced sepsis model. Shock 19: 366–372.
28. Mullins, G.E., J. Sunden-Cullberg, A.S. Johansson, et al. 2004. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 60: 566–573.
29. Buras, J.A., B. Holzmann, and M. Sitkovsky. 2005. Animal models of sepsis: Setting the stage. Nature Reviews Drug Discovery 4: 854–865.
30. Diehl, K.H., R. Hull, D. Morton, et al. 2001. A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology 21: 15–23.
31. Sava, G., L. Perissin, S. Zorzet, and C. Callerio. 1986. Antineoplastic effects of egg-white lysozyme in mice bearing solid metastasizing tumors. Anticancer Research 6: 183–186.
32. Murakami, S., J. Nagai, K. Fujii, R. Yumoto, and M. Takano. 2008. Influences of dosage regimen and co-administration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice. Journal of Antimicrobial Chemotherapy 61: 658–664.
33. Haverdings, R.F.G., M. Haas, A.R. Greupink, et al. 2001. Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting. Renal Failure 23: 397–409.
34. Sama, A.E., J. D’Amore, M.F. Ward, G. Chen, and H. Wang. 2004. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Academic Emergency Medicine 11: 867–873.
35. Berman, R.S., J.D. Frew, and W. Martin. 1993. Endotoxin-induced arterial endothelial barrier dysfunction assessed by an in vitro model. British Journal of Pharmacology 110: 1282–1284.
36. Goldblum, S.E., X. Ding, T.W. Brann, and J. Campbell-Washington. 1993. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: Concurrent F-actin depolymerization and new actin synthesis. Journal of Cellular Physiology 157: 13–23.
37. Wolfson, R.K., E.T. Chiang, and J.G. Garcia. 2011. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvascular Research 81: 189–197.
38. Yang, H., H. Wang, C.J. Czura, and K.J. Tracey. 2005. The cytokine activity of HMGB1. Journal of Leukocyte Biology 78: 1–8.
39. Qin, Y.H., S.M. Dai, G.S. Tang, et al. 2009. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. Journal of Immunology 183: 6244–6250.
40. Sun, C., C. Liang, Y. Ren, et al. 2009. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Research in Cardiology 104: 42–49.
41. Schnittler, H.J., S.W. Schneider, H. Raifer, et al. 2001. Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflügers Archiv 442: 675–687.
42. Friedl, J., M. Puhlmann, D.L. Bartlett, et al. 2002. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: Relationship between the procoagulant and permeability effects of TNF. Blood 100: 1334–1339.
43. Petrache, I., A. Birukova, S.I. Ramirez, J.G. Garcia, and A.D. Verin. 2003. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. American Journal of Respiratory Cell and Molecular Biology 28: 574–581.
44. Andersson, U., H. Wang, K. Palmblad, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 192: 565–570.
45. Hansson, G.K., and P. Libby. 2006. The immune response in atherosclerosis: A double-edged sword. Nature Reviews. Immunology 6: 508–519.
46. Andersson, U., and K.J. Tracey. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology 29: 139–162.
47. Wang, F.P., L. Li, J. Li, J.Y. Wang, L.Y. Wang, and W. Jiang. 2013. High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS One 8, e64373.
48. Lockyer, J.M., J.S. Colladay, W.L. Alperin-Lea, T. Hammond, and A.J. Buda. 1998. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circulation Research 82: 314–320.
49. Rose, B.A., T. Force, and Y. Wang. 2010. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews 90: 1507–1546.
50. Park, J.S., F. Gamboni-Robertson, Q. He, et al. 2006. High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology - Cell Physiology 290: C917–C924.
51. Yang, H., and K.J. Tracey. 2010. Targeting HMGB1 in inflammation. Biochimica et Biophysica Acta 1799: 149–156.
52. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885–891.
53. Bhatia, M., M. He, H. Zhang, and S. Moochhala. 2009. Sepsis as a model of SIRS. Frontiers in Bioscience 14: 4703–4711.
54. Tracey, K.J., Y. Fong, D.G. Hesse, et al. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664.
55. Wichterman, K.A., A.E. Baue, and I.H. Chaudry. 1980. Sepsis and septic shock—a review of laboratory models and a proposal. Journal of Surgical Research 29: 189–201.
56. Wang, H., H. Yang, C.J. Czura, A.E. Sama, and K.J. Tracey. 2001. HMGB1 as a late mediator of lethal systemic inflammation. American Journal of Respiratory and Critical Care Medicine 164: 1768–1773.
57. Ramachandran, G. 2014. Gram-positive and gram-negative bacterial toxins in sepsis: A brief review. Virulence 5: 213–218.
58. Tanida, N., N. Ohno, Y. Adachi, et al. 1992. Modification of immunopharmacological activities of synthetic monosaccharide lipid A analogue, GLA60, by lysozyme. Journal of Biochemistry 112: 616–623.
59. Takada, K., N. Ohno, and T. Yadomae. 1994. Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infection and Immunity 62: 1171–1175.
60. Ohno, N., and D.C. Morrison. 1989. Lipopolysaccharide interaction with lysozyme. Binding of lipopolysaccharide to lysozyme and inhibition of lysozyme enzymatic activity. Journal of Biological Chemistry 264: 4434–4441.
61. Thachil, J., C.H. Toh, M. Levi, and H.G. Watson. 2012. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. British Journal of Haematology 157: 493–494.